The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy
- PMID: 18227842
- DOI: 10.1038/sj.mt.6300372
The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy
Abstract
Gene therapy trials have been performed with virus-based vectors that have the ability to integrate permanently into genomic DNA and thus allow prolonged expression of corrective genes after transduction of hematopoietic stem and progenitor cells. Adverse events observed during the X-linked severe combined immunodeficiency gene therapy trial revealed a significant risk of genotoxicity related to retrovirus vector integration and activation of adjacent proto-oncogenes, with several cases of T-cell leukemia linked to vector activation of the LMO2 gene. In patients with chronic granulomatous disease (CGD), rhesus macaques, and mice receiving hematopoietic stem and progenitor cells transduced with retrovirus vectors, a highly non-random pattern of vector integration has been reported. The most striking finding has been overrepresentation of integrations in one specific genomic locus, a complex containing the MDS1 and the EVI1 genes. Most evidence suggests that this overrepresentation is primarily due to a modification of primitive myeloid cell behavior by overexpression of EVI1 or MDS1-EVI1, as opposed to a specific predilection for integration at this site. Three different proteins can be produced from this complex locus: MDS1, MDS1-EVI1, and EVI1. This review will summarize current knowledge regarding this locus and its gene products, with specific focus on issues with relevance to gene therapy, leukemogenesis, and hematopoiesis. Insights into the mechanisms that result in altered hematopoiesis and leukemogenesis when this locus is dysregulated could improve the safety of gene therapy in the future.
Similar articles
-
Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.Blood. 2005 Oct 1;106(7):2530-3. doi: 10.1182/blood-2005-03-1115. Epub 2005 Jun 2. Blood. 2005. PMID: 15933056 Free PMC article.
-
Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1760-5. doi: 10.1073/pnas.030421197. Proc Natl Acad Sci U S A. 2000. PMID: 10677531 Free PMC article.
-
[The role and regulation of EVI1 in normal hematopoiesis and hematopoietic malignancies].Rinsho Ketsueki. 2024;65(9):954-960. doi: 10.11406/rinketsu.65.954. Rinsho Ketsueki. 2024. PMID: 39358295 Review. Japanese.
-
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.Nat Med. 2006 Apr;12(4):401-9. doi: 10.1038/nm1393. Epub 2006 Apr 2. Nat Med. 2006. PMID: 16582916 Clinical Trial.
-
Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies.Cancer Sci. 2009 Jun;100(6):990-5. doi: 10.1111/j.1349-7006.2009.01152.x. Epub 2009 Mar 9. Cancer Sci. 2009. PMID: 19385966 Free PMC article. Review.
Cited by
-
Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.PLoS One. 2013 Jun 12;8(6):e66510. doi: 10.1371/journal.pone.0066510. Print 2013. PLoS One. 2013. PMID: 23776681 Free PMC article.
-
Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.Hum Gene Ther. 2009 Dec;20(12):1607-26. doi: 10.1089/hum.2009.109. Hum Gene Ther. 2009. PMID: 19689196 Free PMC article.
-
Feline leukemia virus integrase and capsid packaging functions do not change the insertion profile of standard Moloney retroviral vectors.Gene Ther. 2010 Jun;17(6):799-804. doi: 10.1038/gt.2010.24. Epub 2010 Mar 18. Gene Ther. 2010. PMID: 20237508 Free PMC article.
-
Gene therapy of chronic granulomatous disease: the engraftment dilemma.Mol Ther. 2011 Jan;19(1):28-35. doi: 10.1038/mt.2010.232. Epub 2010 Nov 2. Mol Ther. 2011. PMID: 21045810 Free PMC article. Review.
-
Gene Editing and Genotoxicity: Targeting the Off-Targets.Front Genome Ed. 2020 Dec 10;2:613252. doi: 10.3389/fgeed.2020.613252. eCollection 2020. Front Genome Ed. 2020. PMID: 34713236 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical